Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
Medicine name | clobazam (Tapclob®) |
Formulation | 5 mg/5 ml and 10 mg/5 ml oral suspension |
Reference number | 2009 |
Indication | Short-term relief (2-4 weeks) only of anxiety that is severe, disabling or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short term psychosomatic, organic or psychotic illness. The use of clobazam to treat short-term “mild” anxiety is inappropriate and unsuitable. Before treatment of anxiety states associated with emotional instability, it must first be determined whether the patient suffers from a depressive disorder requiring adjunctive or different treatment. Indeed, in patients with anxiety associated with depression, clobazam must be used only in conjunction with adequate concomitant treatment. Use of benzodiazepine (such as clobazam) alone, can precipitate suicide in such patients. In patients with schizophrenic or other psychotic illnesses, use of benzodiazepines is recommended only for adjunctive, i.e. not for primary treatment. Clobazam may be used as adjunctive therapy in epilepsy |
Company | Martindale Pharma |
BNF chapter | Central nervous system |
Assessment type | N/A |
Status | Medicine does not meet criteria for AWMSG assessment |
Date of issue | 24/05/2013 |